1,200 results found

Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement for the commercialization of a biosimilar candidate to Genentech's OCREVUS (ocrelizumab), a treatment for multiple sclerosis. The agreement combines Polpharma Biologics' development expertise with Teva's commercial capabilities across major markets including the United States, Europe, and several other territories. Under the terms, Polpharma Biologics will handle development and manufacturing while Teva manages regul

A recent US jury verdict awarded Viasat $229 million in damages after finding that Kioxia infringed a patent covering flash memory error-correction technology. This case underscores how patents serve...